Physician profile
Bethany Vrouhas
NPI 1417403650
$1,858.43
in general payments reported to CMS, 2019-2025
15 companies · $775 in 2025
The $775 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $233 · 2023: $354 · 2024: $315 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.26 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $990.29 | 2021-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $200.27 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $160.42 | 2025 | Kisunla, Zepbound, Mounjaro |
| Novo Nordisk INC | $137.57 | 2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $62.24 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $54.01 | 2021-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.09 | 2025 | Jardiance |
| Neurocrine Biosciences, INC. | $33.99 | 2023 | Ingrezza |
| Glaxosmithkline, LLC. | $28.01 | 2025 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $27.09 | 2025 | Eliquis |
| Indivior INC. | $25.83 | 2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $24.97 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.19 | 2025 | Caplyta |
| Ardelyx, INC. | $22.61 | 2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $20.85 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Vrouhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.